Bentrio®

Allergy Blocker nasal spray · 20 mL

Altamira Medica AG · Switzerland · in-licensing & distribution

Indication Bentrio® is indicated for the prevention and treatment of symptoms of seasonal or perennial allergic rhinitis caused by inhaled airborne allergens.

The drug-free barrier spray with the world's best clinical evidence.

A physical barrier — no antihistamine, no steroid, no preservatives. Tested against anti-doping lists.

FDA · NMPA · MDR

Cleared in the US, China and the EU — Class IIa medical device

CH · DE

Developed in Switzerland, made in Germany

4 h

Acts for up to 4 hours · reapply as needed

Bentrio® Allergy Blocker



20 mL · nasal spray
Class IIa medical device

OTC

No prescription · not RX

6 yr+

Also in pregnancy and breastfeeding

2.4×

Better symptom relief than saline
NASAR trial · Allergy 2024 · p = 0.013

4

Published clinical studies

US · CN

Patents granted; EU about to close.
Japan, Australia, Eurasia ongoing

Nordics · Hong Kong · EU · China

Marketed and approved today — other territories open / partly in negotiation

Fast

Starts working immediately on contact — no waiting, no drowsiness, no build-up period.

Powerful

Triple action: shields the mucosa, traps inhaled particles and moisturizes.

Free

No drugs, no preservatives — formulated with natural bentonite, a mineral found in nature.

Between saline and medicated sprays — more than saline, without the drug burden.

Bentrio® is a registered trademark of Altamira Medica AG. Regulatory status, claims and pack presentation vary by territory.